Falzone, Y, Sommer, C, Querol, L, Allen, J, Merkies, I, Van Doorn, P, Wallstroem, E, Lu, Y, Alonso-Alonso, M, Atassi, N, Lewis, RA. Riliprubart Phase 3 MOBILIZE and VITALIZE Trials for CIDP are Actively Enrolling Globally. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Stettner, M, Allen, J, Rinaldi, S, Pinter, GL, Querol, L, Magy, L, De Roeck, A, Van Hoorick, B, Hofman, E, Istas, G, Skripuletz, T, Lewis, R, Van Doorn, PA. Efgartigimod in Pretreated CIDP With Persistent Disease Activity or Progressive/Relapsing Active Disease: ADHERE Analysis. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Wiegers, E, Steyerberg, E, Rajpar, A, Paliwal, P, Kanani, K, Kroon, HA, Dananberg, J, Cornblath, D, Willison, H, Kim, M, Gorson, K, Querol, L, Hartung, HP, Islam, Z, van Doorn, PA, Jacobs, B. Comparative Effectiveness In IGOS: ANX005 Versus Intravenous Immunoglobulin or Plasma Exchange For Guillain-Barre Syndrome. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Dymm, B, Van den Bergh, P, London, Z, Lewis, R, Querol, L, Harbo, T, Allen, J, Hadden, R, Van Doorn, PA. Development and Validation of a Digital Tool to Simplify Use of Guidelines For CIDP Diagnosis. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).